Articles Tagged With: bezlotoxumab
-
Clostridioides difficile Infection: Guideline Update
Fidaxomicin is preferred over vancomycin for initial and recurrent cases. Bezlotoxumab is recommended in many cases of recurrent infection and initial infection in patients at high risk of recurrence.
-
Oral Vancomycin Is the Most Cost-effective Treatment for the First Recurrence of Clostridium Difficile Infection
The authors of a pharmacoeconomic study comparing bezlotoxumab plus oral vancomycin, oral vancomycin alone, and fidaxomicin found that oral vancomycin alone was the most cost-effective regimen to treat the first recurrence of Clostridium difficile infection.
-
Bezlotoxumab Injection (Zinplava)